Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGNATURE: Sonidegib in PTCH1 or SMO mutated tumors
NCT02002689Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2014
- Primary completion
- Mar 2015
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of sonidegib in solid tumor, hematologic malignancy, sponsored by Novartis. Started Feb 2014; status: terminated.
02
Drugs
sonidegib
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT02002689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02002689.